Summit Therapeutics Plc Stock Investor Sentiment
| SMMT Stock | USD 18.46 0.48 2.53% |
Slightly above 53% of Summit Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Summit Therapeutics PLC suggests that some traders are interested. Summit Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Summit Therapeutics' earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
53
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Summit Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Summit Therapeutics PLC.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentAcquiring |
Summit Historical Sentiment
Although Summit Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Summit, such as negative comments on social media and news outlets, may cause fear in the market and push Summit Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Summit.
Summit |
Summit Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Summit Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Summit Therapeutics PLC Historical Investor Sentiment
Investor biases related to Summit Therapeutics' public news can be used to forecast risks associated with an investment in Summit. The trend in average sentiment can be used to explain how an investor holding Summit can time the market purely based on public headlines and social activities around Summit Therapeutics PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Summit Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Summit Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Summit Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Summit Therapeutics.
Far too much social signal, news, headlines, and media speculation about Summit Therapeutics that are available to investors today. That information is available publicly through Summit media outlets and privately through word of mouth or via Summit internal channels. However, regardless of the origin, that massive amount of Summit data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Summit Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Summit Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Summit Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Summit Therapeutics alpha.
Summit Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Summit Therapeutics files to sell 10.35M shares of common stock for holders | 09/19/2024 |
2 | Acquisition by Mahatme Ujwala of 40500 shares of Summit Therapeutics at 1.67 subject to Rule 16b-3 | 09/20/2024 |
3 | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 10/04/2024 |
4 | Acquisition by Clark Kenneth A of 200000 shares of Summit Therapeutics at 19.95 subject to Rule 16b-3 | 10/11/2024 |
5 | Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You | 10/22/2024 |
6 | Summit Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Advances and ... | 10/31/2024 |
7 | Why Summit Therapeutics Stock Was a Winner Today | 11/04/2024 |
8 | SMMT Surges as Analyst Initiates Coverage with Buy Rating | 11/05/2024 |
9 | 2 Hot Biopharma Stocks to Buy and Hold for 5 Years | 11/08/2024 |
10 | Merck Inks 3.3B Licensing Deal With Chinese Biotech for Cancer Therapy | 11/15/2024 |
11 | Summit Therapeutics Shares Down 5.9 percent Should You Sell | 11/20/2024 |
12 | Summit Therapeutics to Present at Upcoming Investor Conferences | 11/26/2024 |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.